Cargando…

Dynamic changes of bone metastasis predict bone‐predominant status to benefit from radium‐223 dichloride for patients with castration‐resistant prostate cancer

BACKGROUND: To best employ radium‐223 dichloride (Ra‐223) for patients with castration‐resistant prostate cancer (CRPC) and bone metastasis, we investigated the bone‐predominant status in patients treated with Ra‐223. METHODS: We retrospectively evaluated 127 CRPC patients who underwent treatment wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashimoto, Kohei, Miyoshi, Yasuhide, Shindo, Tetsuya, Hori, Masakazu, Tsuboi, Yasumasa, Kobayashi, Ko, Fukuta, Fumimasa, Tanaka, Toshiaki, Miyamoto, Shintaro, Maehana, Takeshi, Okada, Manabu, Nishiyama, Naotaka, Yanase, Masahiro, Kato, Ryuichi, Hotta, Hiroshi, Kunishima, Yasuharu, Takahashi, Atsushi, Hinotsu, Shiro, Sakata, Koh‐ichi, Kitamura, Hiroshi, Uemura, Hiroji, Masumori, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666734/
https://www.ncbi.nlm.nih.gov/pubmed/32964674
http://dx.doi.org/10.1002/cam4.3459
_version_ 1783610188281937920
author Hashimoto, Kohei
Miyoshi, Yasuhide
Shindo, Tetsuya
Hori, Masakazu
Tsuboi, Yasumasa
Kobayashi, Ko
Fukuta, Fumimasa
Tanaka, Toshiaki
Miyamoto, Shintaro
Maehana, Takeshi
Okada, Manabu
Nishiyama, Naotaka
Yanase, Masahiro
Kato, Ryuichi
Hotta, Hiroshi
Kunishima, Yasuharu
Takahashi, Atsushi
Hinotsu, Shiro
Sakata, Koh‐ichi
Kitamura, Hiroshi
Uemura, Hiroji
Masumori, Naoya
author_facet Hashimoto, Kohei
Miyoshi, Yasuhide
Shindo, Tetsuya
Hori, Masakazu
Tsuboi, Yasumasa
Kobayashi, Ko
Fukuta, Fumimasa
Tanaka, Toshiaki
Miyamoto, Shintaro
Maehana, Takeshi
Okada, Manabu
Nishiyama, Naotaka
Yanase, Masahiro
Kato, Ryuichi
Hotta, Hiroshi
Kunishima, Yasuharu
Takahashi, Atsushi
Hinotsu, Shiro
Sakata, Koh‐ichi
Kitamura, Hiroshi
Uemura, Hiroji
Masumori, Naoya
author_sort Hashimoto, Kohei
collection PubMed
description BACKGROUND: To best employ radium‐223 dichloride (Ra‐223) for patients with castration‐resistant prostate cancer (CRPC) and bone metastasis, we investigated the bone‐predominant status in patients treated with Ra‐223. METHODS: We retrospectively evaluated 127 CRPC patients who underwent treatment with Ra‐223. The patients were divided into three groups based on the types of dynamic changes of bone metastasis between diagnosis and just before Ra‐223: (a) only known lesions; (b) de novo lesions; (c) new progressive lesions. We developed the risk assessment using predictive factors based on progression‐free survival (PFS). RESULTS: During the median follow‐up period of 10.4 months, the median PFS in the only known lesions group was 11.3 months compared to 8.1 months in the de novo lesions group and 5.1 months in the new progressive lesions group (P < .001). In multivariate analysis, the type of the new progressive lesions in bone metastasis (HR 1.45, 95% CI 1.13‐1.66, P = .003), performance status of >1 (HR 1.74, 95% CI 1.04‐2.89, P = .034), PSA value of >100 ng/mL (HR 1.59, 95% CI 1.02‐2.50, P = .043), and PSA doubling time (PSADT) of <3 months (HR 1.53, 95% CI 1.11‐2.03, P = .007) were independent unfavorable predictive factors for PFS. The risk assessment for PFS was highlighted when the type of dynamic changes of bone metastasis was combined with PSADT just before Ra‐223 treatment. This was associated with non‐bone metastasis progression, especially visceral metastasis, and overall survival. CONCLUSIONS: Risk assessment in combination with dynamic changes of bone metastasis and PSADT determines the bone‐predominant metastasis type to benefit from Ra‐223.
format Online
Article
Text
id pubmed-7666734
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-76667342020-11-20 Dynamic changes of bone metastasis predict bone‐predominant status to benefit from radium‐223 dichloride for patients with castration‐resistant prostate cancer Hashimoto, Kohei Miyoshi, Yasuhide Shindo, Tetsuya Hori, Masakazu Tsuboi, Yasumasa Kobayashi, Ko Fukuta, Fumimasa Tanaka, Toshiaki Miyamoto, Shintaro Maehana, Takeshi Okada, Manabu Nishiyama, Naotaka Yanase, Masahiro Kato, Ryuichi Hotta, Hiroshi Kunishima, Yasuharu Takahashi, Atsushi Hinotsu, Shiro Sakata, Koh‐ichi Kitamura, Hiroshi Uemura, Hiroji Masumori, Naoya Cancer Med Cancer Biology BACKGROUND: To best employ radium‐223 dichloride (Ra‐223) for patients with castration‐resistant prostate cancer (CRPC) and bone metastasis, we investigated the bone‐predominant status in patients treated with Ra‐223. METHODS: We retrospectively evaluated 127 CRPC patients who underwent treatment with Ra‐223. The patients were divided into three groups based on the types of dynamic changes of bone metastasis between diagnosis and just before Ra‐223: (a) only known lesions; (b) de novo lesions; (c) new progressive lesions. We developed the risk assessment using predictive factors based on progression‐free survival (PFS). RESULTS: During the median follow‐up period of 10.4 months, the median PFS in the only known lesions group was 11.3 months compared to 8.1 months in the de novo lesions group and 5.1 months in the new progressive lesions group (P < .001). In multivariate analysis, the type of the new progressive lesions in bone metastasis (HR 1.45, 95% CI 1.13‐1.66, P = .003), performance status of >1 (HR 1.74, 95% CI 1.04‐2.89, P = .034), PSA value of >100 ng/mL (HR 1.59, 95% CI 1.02‐2.50, P = .043), and PSA doubling time (PSADT) of <3 months (HR 1.53, 95% CI 1.11‐2.03, P = .007) were independent unfavorable predictive factors for PFS. The risk assessment for PFS was highlighted when the type of dynamic changes of bone metastasis was combined with PSADT just before Ra‐223 treatment. This was associated with non‐bone metastasis progression, especially visceral metastasis, and overall survival. CONCLUSIONS: Risk assessment in combination with dynamic changes of bone metastasis and PSADT determines the bone‐predominant metastasis type to benefit from Ra‐223. John Wiley and Sons Inc. 2020-09-22 /pmc/articles/PMC7666734/ /pubmed/32964674 http://dx.doi.org/10.1002/cam4.3459 Text en © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Cancer Biology
Hashimoto, Kohei
Miyoshi, Yasuhide
Shindo, Tetsuya
Hori, Masakazu
Tsuboi, Yasumasa
Kobayashi, Ko
Fukuta, Fumimasa
Tanaka, Toshiaki
Miyamoto, Shintaro
Maehana, Takeshi
Okada, Manabu
Nishiyama, Naotaka
Yanase, Masahiro
Kato, Ryuichi
Hotta, Hiroshi
Kunishima, Yasuharu
Takahashi, Atsushi
Hinotsu, Shiro
Sakata, Koh‐ichi
Kitamura, Hiroshi
Uemura, Hiroji
Masumori, Naoya
Dynamic changes of bone metastasis predict bone‐predominant status to benefit from radium‐223 dichloride for patients with castration‐resistant prostate cancer
title Dynamic changes of bone metastasis predict bone‐predominant status to benefit from radium‐223 dichloride for patients with castration‐resistant prostate cancer
title_full Dynamic changes of bone metastasis predict bone‐predominant status to benefit from radium‐223 dichloride for patients with castration‐resistant prostate cancer
title_fullStr Dynamic changes of bone metastasis predict bone‐predominant status to benefit from radium‐223 dichloride for patients with castration‐resistant prostate cancer
title_full_unstemmed Dynamic changes of bone metastasis predict bone‐predominant status to benefit from radium‐223 dichloride for patients with castration‐resistant prostate cancer
title_short Dynamic changes of bone metastasis predict bone‐predominant status to benefit from radium‐223 dichloride for patients with castration‐resistant prostate cancer
title_sort dynamic changes of bone metastasis predict bone‐predominant status to benefit from radium‐223 dichloride for patients with castration‐resistant prostate cancer
topic Cancer Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666734/
https://www.ncbi.nlm.nih.gov/pubmed/32964674
http://dx.doi.org/10.1002/cam4.3459
work_keys_str_mv AT hashimotokohei dynamicchangesofbonemetastasispredictbonepredominantstatustobenefitfromradium223dichlorideforpatientswithcastrationresistantprostatecancer
AT miyoshiyasuhide dynamicchangesofbonemetastasispredictbonepredominantstatustobenefitfromradium223dichlorideforpatientswithcastrationresistantprostatecancer
AT shindotetsuya dynamicchangesofbonemetastasispredictbonepredominantstatustobenefitfromradium223dichlorideforpatientswithcastrationresistantprostatecancer
AT horimasakazu dynamicchangesofbonemetastasispredictbonepredominantstatustobenefitfromradium223dichlorideforpatientswithcastrationresistantprostatecancer
AT tsuboiyasumasa dynamicchangesofbonemetastasispredictbonepredominantstatustobenefitfromradium223dichlorideforpatientswithcastrationresistantprostatecancer
AT kobayashiko dynamicchangesofbonemetastasispredictbonepredominantstatustobenefitfromradium223dichlorideforpatientswithcastrationresistantprostatecancer
AT fukutafumimasa dynamicchangesofbonemetastasispredictbonepredominantstatustobenefitfromradium223dichlorideforpatientswithcastrationresistantprostatecancer
AT tanakatoshiaki dynamicchangesofbonemetastasispredictbonepredominantstatustobenefitfromradium223dichlorideforpatientswithcastrationresistantprostatecancer
AT miyamotoshintaro dynamicchangesofbonemetastasispredictbonepredominantstatustobenefitfromradium223dichlorideforpatientswithcastrationresistantprostatecancer
AT maehanatakeshi dynamicchangesofbonemetastasispredictbonepredominantstatustobenefitfromradium223dichlorideforpatientswithcastrationresistantprostatecancer
AT okadamanabu dynamicchangesofbonemetastasispredictbonepredominantstatustobenefitfromradium223dichlorideforpatientswithcastrationresistantprostatecancer
AT nishiyamanaotaka dynamicchangesofbonemetastasispredictbonepredominantstatustobenefitfromradium223dichlorideforpatientswithcastrationresistantprostatecancer
AT yanasemasahiro dynamicchangesofbonemetastasispredictbonepredominantstatustobenefitfromradium223dichlorideforpatientswithcastrationresistantprostatecancer
AT katoryuichi dynamicchangesofbonemetastasispredictbonepredominantstatustobenefitfromradium223dichlorideforpatientswithcastrationresistantprostatecancer
AT hottahiroshi dynamicchangesofbonemetastasispredictbonepredominantstatustobenefitfromradium223dichlorideforpatientswithcastrationresistantprostatecancer
AT kunishimayasuharu dynamicchangesofbonemetastasispredictbonepredominantstatustobenefitfromradium223dichlorideforpatientswithcastrationresistantprostatecancer
AT takahashiatsushi dynamicchangesofbonemetastasispredictbonepredominantstatustobenefitfromradium223dichlorideforpatientswithcastrationresistantprostatecancer
AT hinotsushiro dynamicchangesofbonemetastasispredictbonepredominantstatustobenefitfromradium223dichlorideforpatientswithcastrationresistantprostatecancer
AT sakatakohichi dynamicchangesofbonemetastasispredictbonepredominantstatustobenefitfromradium223dichlorideforpatientswithcastrationresistantprostatecancer
AT kitamurahiroshi dynamicchangesofbonemetastasispredictbonepredominantstatustobenefitfromradium223dichlorideforpatientswithcastrationresistantprostatecancer
AT uemurahiroji dynamicchangesofbonemetastasispredictbonepredominantstatustobenefitfromradium223dichlorideforpatientswithcastrationresistantprostatecancer
AT masumorinaoya dynamicchangesofbonemetastasispredictbonepredominantstatustobenefitfromradium223dichlorideforpatientswithcastrationresistantprostatecancer